Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PREDICT - Prospective Observational Study Of A Cohort Of Naive Patients With Chronic Hepatitis C Infected With HCV Genotype 1 Low Viral Load (HCV LVL 1) And Treated With Peg-Intron [peginterferon alfa 2b] 1.5 ug/Kg/Week Plus Rebetol [ribavirin] 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24

Next Previous
Search
Trial Profile

PREDICT - Prospective Observational Study Of A Cohort Of Naive Patients With Chronic Hepatitis C Infected With HCV Genotype 1 Low Viral Load (HCV LVL 1) And Treated With Peg-Intron [peginterferon alfa 2b] 1.5 ug/Kg/Week Plus Rebetol [ribavirin] 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PREDICT
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 12 Jan 2011 Planned End Date changed from 1 Nov 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov [NCT01054742].
    • 12 Jan 2011 Planned End Date changed from 1 Nov 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov [NCT01054742].
    • 12 Jan 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov [NCT01054742].

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top